As attacks continue to be carried out across the Middle East, there are growing concerns about the ones that haven’t yet ...

Eighty-five original research projects from aspiring physician-scientists were on display at the 2026 Medical Student Research Forum at the Jacobs School of Medicine and Biomedical Sciences.

This study presents valuable findings implicating nuclear export in the regulation of protein condensate behaviour and TDP-43 phase behaviour, suggesting a link to pathogenic aggregation in ALS/FTD.

Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company pioneering precision medicines that modulate regulatory T cells (Tregs) to rebalance immune function in patients with autoimmune ...

U.S. scientists have discovered a hidden molecular “switch” that herpes viruses rely on to invade cells. By combining AI, ...

Secretary of State Marco Rubio on Friday rolled out a new diplomatic scarlet letter for Tehran, announcing that the United States has formally designated Iran as a “State Sponsor of Wrongful Detention ...

The FBI designates Iran a State Sponsor of Wrongful Detention and offers $25M for kidnapped Americans as US–Iran war tensions ...

The research in this week’s report investigates new energy storage materials and processes and advanced nuclear and fusion power ...

A proof-of-concept study opens up an avenue for treating solid tumours that express low levels of a target antigen.

Nuclear fusion group SHINE Technologies said it has raised $240 million in equity funding to advance the company's commercial ...

Positive Phase 3 data from ORIGIN 3 study of atacicept in IgA nephropathy (IgAN) presented at American Society of Nephrology (ASN) Kidney Week ...

SHINE Technologies, a nuclear fusion company, today announced it has raised $240 million in equity funding, and appointed Dr. Patrick Soon-Shiong, M.D., Executive Chairman of ImmunityBio and founder ...